Oric Pharmaceuticals Inc ((ORIC)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Oric Pharmaceuticals Inc. is conducting a clinical study titled ‘An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration.’ The study aims to determine the recommended Phase 2 dose, evaluate safety, and assess the antitumor activity of ORIC-114 in patients with advanced solid tumors with EGFR or HER2 alterations.
The study tests ORIC-114, an oral drug administered daily, both as a single agent and in combination with a chemotherapy drug. The goal is to find the optimal dosing regimen and evaluate its effectiveness in treating solid tumors.
This interventional study follows a non-randomized, sequential model with no masking, focusing primarily on treatment. The study uses a 3+3 dose escalation design to determine safe and effective dosing.
The study began on March 24, 2022, with the latest update submitted on July 31, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
The outcome of this study could significantly impact Oric Pharmaceuticals’ stock performance by demonstrating the potential of ORIC-114 in treating solid tumors. Positive results may enhance investor confidence and position the company as a leader in cancer treatment innovation.
The study is currently recruiting, with further details available on the ClinicalTrials portal.